An Australian stem cell and regenerative medicine company

September 13, 2019

Trading Halt

View Report

July 01, 2019

Shaw and Partners Research Update: “A Key Strategic Position in the Emerging Stem Cell Therapeutic Market; ‘Buy’ Rating; Price Target $2.50”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

May 23, 2019

Shaw and Partners Research Update: “Management and Board Additions Indicate Confidence; ‘Buy’ Rating; Price Target $2.50

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

March 28, 2019

Shaw and Partners Research Update: “Extension of Option Delivers Buying Opportunity; ‘Buy’ Rating; Price Target $2.50”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

March 25, 2019

H.C. Wainwright & Co. Research Update: “FUJIFILM Delay Merely a Bump in the Road, We Believe; Reiterate Buy”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating his “BUY” Rating